Dr. Luis Lopez, Corgenix Medical Director, was awarded the European Atherosclerosis Society 2017 Poster Award for his abstract presentation at the 85th Congress which took place in Prague, Czech Republic April 23-26, 2017. The poster, titled “Relationship of Platelet Thromboxane Inhibition by Aspirin and All-Cause Mortality in Patients With Stable Coronary Artery Disease”, involved testing for urinary 11 dehydro Thromboxane B2 (11dhTxB2) levels using the Corgenix test kit in patients with Coronary Artery Disease (CAD). The study was done in conjunction with the Baylor Heart and Vascular Institute and lead investigator Dr. Peter McCullough.
This work was also published in the American Journal of Cardiology: “Urinary 11 dehydro Thromboxane B2 and Mortality in Patients with Stable Coronary Artery Disease” McCullough P et al, AJC 2017, 119: 7,972-977. The study followed 449 CAD patients over five years. About 85 percent of them survived beyond that five-year mark, with one thing in common: they had lower levels of 11dhTxB2 in their urine. Most of them averaged less than 1,500 pg/mL of the substance. Such evidence points to growing interest in 11dhTxB2, which via urine testing can help inform dosage plans for preventive aspirin in CAD patients. Dr. McCullough explained the study’s approach:
“Say for example, you have coronary artery disease and your doctor prescribes a ‘baby dose’ of aspirin (about 81mg a day) to keep the risk of a heart attack at bay. You take that dose for about 2 weeks, and then take the urine test. You score a 2,500. It’s too high, so your doctor ups your dose to the 325mg full dose. After another 2 weeks, you retake the test. You score 1,800. Better, but still above 1,500. Now, your doctors know that for whatever reason, aspirin just isn’t enough for you. It’s time to up the medicine mix to something else – Plavix (clopidogrel), maybe. And after that, they can test you (and retest you) until your numbers get in the safe, survival zone of 1,500”
The Corgenix 11dhTxB2 Test Kit is an enzyme-linked immunoassay (ELISA) to determine levels of 11 dehydro Thromboxane B2 (11dhTxB2) in human urine, which aids in the qualitative detection of acetylsalicylic acid (ASA) effect in apparently healthy individuals post ingestion. The test is FDA cleared and approved in the US and CE marked for use in the EU.
We invite you to join Dr. Lopez, where he will present information from this study at the press briefing room (room S2) on Tuesday, July 11 during the ISTH 2017 Congress from 9:00-10:30 am. Representatives of Corgenix will also be available in the exhibit hall at booth 653, Hall 6.2.